Drug
Glucagon-Like Peptide 1 clinical trials
Also written GLP-1.
Keep track of what changes. Save the Glucagon-Like Peptide 1 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2008 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 42
Rigshospitalet, Denmark (3) · University Hospital, Gentofte, Copenhagen (3) · Johns Hopkins University (3) · University of Maryland, Baltimore (2) · Papworth Hospital NHS Foundation Trust (2) · University of Pennsylvania (2) · University of Aarhus (2) · Hvidovre University Hospital (2)
Often tested with
Tested in the same studies.
Gastric Inhibitory Polypeptide (7) · Avexitide (2) · Glimepiride (1) · Insulin, Regular, Human (1) · Amino Acids (1) · Peptide YY human (3-36) (1) · Naltrexone (1) · Atropine (1)
Studies
Open first, then newest update. How each study uses Glucagon-Like Peptide 1 is read from its arms, and is right about nine times in ten.
Testing it · 44
- Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With ObesityNot yet recruitingPhase 2Indiana UniversityNCT07823452Written as gut-brain axis (GLP-1)-activating food carbohydrate
- Combination Therapy for Alcohol Use DisorderNot yet recruitingPhase 2Johns Hopkins UniversityNCT07249554Written as Glucagon-Like Peptide-1 Agonist (GLP-1)
- The Effects of LEUVATE on Glycemia, Insulinemia, Aminoacidemia, and Protein Synthesis in GLP-1 RA-treated AdultsNot yet recruitingNot applicableNutraceutical Innovations LLCNCT07595575Written as GLP-1
- Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 InfusionRecruitingNot applicableRigshospitalet, DenmarkNCT07398300Written as GLP-1
- Beta-cell Response to Incretin Hormones in Cystic FibrosisRecruitingNot applicableUniversity of PennsylvaniaNCT01851694Written as GLP-1
- Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass SurgeryRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT00992901Written as GLP-1 and GIP
- Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity MeasuresEnrolling by invitationEarly Phase 1AgelessRxNCT07092605Written as GLP-1
- GLP-1 Medicines and Mental Health ChangesCompletedNot applicableUniversity of California, San DiegoNCT07368855Written as GLP-1
- Glucagon-like Peptide-1 in Type 1 DiabetesWithdrawnEarly Phase 1University of Maryland, BaltimoreNCT04355832Written as Glucagon-like peptide-1
- GLP-1 and HypoglycemiaActive, not recruitingEarly Phase 1University of Maryland, BaltimoreNCT01858896Written as Glucagon-Like Peptide- 1 (GLP-1) infusion
- Effect of GLP-1 on Insulin Biosynthesis and Turnover RatesTerminatedPhase 1/2Albert Einstein College of MedicineNCT00609154Written as glucagon like peptide-1
- Incretin Action in Physiology and DiabetesCompletedPhase 1David D'Alessio, M.D.NCT02550548Written as GLP-1 infusion
- Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon LiraglutidTerminatedPhase 3Universitätsklinikum Hamburg-EppendorfNCT02417103Written as GLP-1 (Liraglutide)
- Effect of GLP-1 on Microvascular Insulin Responses in Type 1 DiabetesWithdrawnEarly Phase 1University of VirginiaNCT04133922Written as GLP-1
- Acute Effects of GLP-1 on Renal HemodynamicsCompletedNot applicableRigshospitalet, DenmarkNCT04337268Written as Glucagon-Like Peptide 1
- The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without SulphonylureaCompletedNot applicableUniversity Hospital, Gentofte, CopenhagenNCT03081676Written as Glucagon-like Peptide-1
- GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in HumansCompletedPhase 1Uppsala UniversityNCT02731664Written as GLP-1
- GLP-1 Loading During Elective Percutaneous Coronary InterventionStatus unknownPhase 2Papworth Hospital NHS Foundation TrustNCT02127996Written as GLP-1
- Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal MuscleCompletedNot applicableUniversity of NottinghamNCT02370745Written as GLP-1
- The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart FailureCompletedPhase 1Papworth Hospital NHS Foundation TrustNCT02129179Written as Glucagon-Like Peptide 1
See all 44 studies that test Glucagon-Like Peptide 1 →
As the comparator · 4 — what is tested is compared with Glucagon-Like Peptide 1
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshNot yet recruitingPhase 4Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersNCT06449235Written as Glucagon-Like Peptide-1
- Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity SurgeryCompletedPhase 1Turku University HospitalNCT01880827Written as GLP-1
- To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.CompletedNot applicableUniversity of PisaNCT03414333Written as GLP-1
- Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1CompletedNot applicableRigshospitalet, DenmarkNCT01347801Written as GLP-1
Codes
What other systems call Glucagon-Like Peptide 1 · ClinicalTrials.gg INT008875
- MeSH (NLM) D052216Glucagon-Like Peptide 1One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D052216 | Glucagon-Like Peptide 1 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.